BioAffinity Net Working Capital from 2010 to 2024

BIAFW Stock  USD 0.57  0.13  18.57%   
BioAffinity Technologies Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital is likely to outpace its year average in 2024. During the period from 2010 to 2024, BioAffinity Technologies Net Working Capital regression line of quarterly data had mean square error of 30.1 T and geometric mean of  8,642,751. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
1.7 M
Current Value
1.8 M
Quarterly Volatility
6.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioAffinity Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAffinity Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 262.1 K, Interest Expense of 35.3 K or Gross Profit of 831.2 K, as well as many indicators such as Price To Sales Ratio of 4.82, Dividend Yield of 0.0 or PTB Ratio of 2.78. BioAffinity financial statements analysis is a perfect complement when working with BioAffinity Technologies Valuation or Volatility modules.
  
Check out the analysis of BioAffinity Technologies Correlation against competitors.

Latest BioAffinity Technologies' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of bioAffinity Technologies Warrant over the last few years. It is BioAffinity Technologies' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioAffinity Technologies' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

BioAffinity Net Working Capital Regression Statistics

Arithmetic Mean(7,884,302)
Geometric Mean8,642,751
Coefficient Of Variation(86.89)
Mean Deviation5,068,265
Median(11,002,029)
Standard Deviation6,850,656
Sample Variance46.9T
Range22.4M
R-Value0.64
Mean Square Error30.1T
R-Squared0.40
Significance0.01
Slope974,222
Total Sum of Squares657T

BioAffinity Net Working Capital History

20241.8 M
20231.7 M
202210.8 M
2021-11.6 M

About BioAffinity Technologies Financial Statements

BioAffinity Technologies investors use historical fundamental indicators, such as BioAffinity Technologies' Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioAffinity Technologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital1.7 M1.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioAffinity Stock Analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.